DIARYLETHER INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE
摘要:
The design and synthesis of simple nonpeptide inhibitors of farnesyl-protein transferase (FTase) are described. Cysteine-derived diarylether frameworks are appropriate structural replacements for the C-terminal tetrapeptide portion of the Ras protein, and possess in vitro potency against FTase. Inhibitory activity is dependent on the ring-substitution pattern, and does not require the presence of a C-terminal carboxylate group. (C) 1997 Elsevier Science Ltd.
DIARYLETHER INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE
摘要:
The design and synthesis of simple nonpeptide inhibitors of farnesyl-protein transferase (FTase) are described. Cysteine-derived diarylether frameworks are appropriate structural replacements for the C-terminal tetrapeptide portion of the Ras protein, and possess in vitro potency against FTase. Inhibitory activity is dependent on the ring-substitution pattern, and does not require the presence of a C-terminal carboxylate group. (C) 1997 Elsevier Science Ltd.
[EN] INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE<br/>[FR] INHIBITEURS DE FARNESYL-PROTEINE TRANSFERASE
申请人:MERCK & CO., INC.
公开号:WO1996030014A1
公开(公告)日:1996-10-03
(EN) The present invention comprises peptidomimetic compounds which comprise a suitably aniline and aminoalkylbenzene moieties. The instant compounds inhibit the farnesyl-protein transferase enzyme and the farnesylation of certain proteins. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.(FR) La présente invention concerne des composés peptidomimétiques comprenant une aniline appropriée et des fractions d'aminoalkylbenzène. Les composés instantanés inhibent la farnésyl-protéine transférase et la farnélysation de certaines protéines. L'invention concerne en outre des compositions chimiques thérapeutiques contenant les composés de la présente invention, et des procédés d'inhibition de la farnésyl-protéine transférase ainsi que la farnélysation de la protéine d'oncogène Ras.